Bio-Matrix Scientific Group Inc., a biotech research and development company, recently made a joint announcement with its subsidiary Entest BioMedical Inc. (ENTB.OB), a testing center for various diseases, that they have reached a definitive agreement with Therinject LLC for the development of a immune-therapeutic cancer vaccine.

The companies will first focus on the veterinary market, treating animals with tumors. It’s a market that Bio-Matrix chairman and CEO David Koos says is a significant one. The company anticipates treating thousands of animals, generating millions in revenues.

“Cancer is the No. 1 cause of death among dogs. It’s estimated that one out of every three dogs will get cancer. We anticipate this immuno-therapeutic cancer vaccine could have an efficacy rate of as high as 60 percent where 15 percent to 20 percent is the current cure rate,” Koos stated in the press release. “We believe that during the first year this immuno-therapeutic vaccine is available we will treat roughly 2,000 animals resulting in $3,000 revenue per animal or $6 million in first year revenue from veterinary medical applications. The Company anticipates a market niche over the subsequent five years of 40,000 animals being treated. This is before we expand to human clinical trials.”

Bio-Matrix’s various storage facilities will be used for further research and development of immune-therapeutic treatments for cancer, with a long-term goal utilizing data and technology in support of human clinical trials.

Therinject’s Chief Scientific Officer Steven Josephs Ph.D. explained immune-therapy, expected efficacy rates, and the treatment’s affect on the body.

“For many cancers, efficacy rates should be much higher than currently available therapies. Immuno-therapy stimulates the body’s own immune system to engage in the treatment process. The development of an anti-cancer immune response would be very effective in dealing with metastatic tumors especially in cases where surgery would no longer be feasible.”

As per the agreement, Therinject will work collaboratively with Entest BioMedical’s team to develop intellectual property in this area of cancer treatment, with the ultimate goal of obtaining patents applied by Entest BioMedical’s.